Brief: Algernon Pharma Announces Green Light From Data And Safety Monitoring Board To Continue Multinational 2b/3 Human Study Of Ifenprodil For Treatment Of Covid-19
30/10/2020 12:16
Oct 30 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMA - GREEN LIGHT FROM DATA AND SAFETY
MONITORING
BOARD TO CONTINUE MULTINATIONAL 2B/3 HUMAN STUDY OF IFENPRODIL
FOR TREATMENT OF COVID-19
Source text for Eikon: ID:nGNX7tPD7b
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement